Business Description
ISIN : US79957L1008
Total Employee Number:
108Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 6.11 | |||||
Debt-to-EBITDA | 4.91 | |||||
Interest Coverage | 1.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.86 | |||||
Beneish M-Score | -4.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 27.3 | |||||
3-Year Book Growth Rate | -49.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 88.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.98 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.37 | |||||
9-Day RSI | 76.71 | |||||
14-Day RSI | 77.9 | |||||
3-1 Month Momentum % | 10.56 | |||||
6-1 Month Momentum % | 26.47 | |||||
12-1 Month Momentum % | -23.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.58 | |||||
Quick Ratio | 2.3 | |||||
Cash Ratio | 1.23 | |||||
Days Inventory | 166.2 | |||||
Days Sales Outstanding | 41.39 | |||||
Days Payable | 69.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | -3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.03 | |||||
Operating Margin % | 9.34 | |||||
Net Margin % | -29.15 | |||||
EBITDA Margin % | 9 | |||||
FCF Margin % | 4.1 | |||||
OCF Margin % | 5.19 | |||||
ROE % | -256.29 | |||||
ROA % | -41.99 | |||||
ROIC % | 18.02 | |||||
3-Year ROIIC % | 484.58 | |||||
ROC (Joel Greenblatt) % | 113.12 | |||||
ROCE % | 11.47 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 188.91 | |||||
PE Ratio without NRI | 212.09 | |||||
PS Ratio | 2.77 | |||||
PB Ratio | 40.2 | |||||
Price-to-Free-Cash-Flow | 65.58 | |||||
Price-to-Operating-Cash-Flow | 52.38 | |||||
EV-to-EBIT | 50.28 | |||||
EV-to-EBITDA | 35.47 | |||||
EV-to-Revenue | 3.19 | |||||
EV-to-Forward-Revenue | 2.96 | |||||
EV-to-FCF | 77.87 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Median-PS-Value | 0.94 | |||||
Earnings Yield (Greenblatt) % | 1.99 | |||||
FCF Yield % | 1.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SMTI
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Sanara MedTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 109.816 | ||
| EPS (TTM) ($) | -3.71 | ||
| Beta | 1.5851 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.08 | ||
| Volatility % | 74.34 | ||
| 14-Day RSI | 77.9 | ||
| 14-Day ATR ($) | 0.578218 | ||
| 20-Day SMA ($) | 34.24747 | ||
| 12-1 Month Momentum % | -23.84 | ||
| 52-Week Range ($) | 16.0465 - 35.95 | ||
| Shares Outstanding (Mil) | 9.19 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanara MedTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanara MedTech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 77 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 76 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:00 | 34.33 (+0.23%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 34.33 (+0.23%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 20.97 (-1.36%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 08:00 | 18.02 (-2.07%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 18.02 (-2.07%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:00 | 18.34 (-2.19%) | ||
| Annual report for 2025 | 2026-03-24 | 18.34 (-2.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 18.34 (-2.19%) |
Sanara MedTech Inc Frequently Asked Questions
Guru Commentaries on NAS:SMTI
Sanara Medtech ($SMTI) continues to be an extremely favorable risk reward. On their fourth quarter call they offered revenue guidance of 13-17% growth in line with sell side expectations but below the 20% some hoped for. At their valuation, we believe the forecasted growth to be more than good enough and likely to be revised upward. Perhaps underappreciated is that Sanara’s products are largely distributed by third parties who, to be effective, need to be at a hospital for a procedure - to ensure Sanara’s products are used. With increasing evidence of their product’s efficacy recently released and a focus on increasing per hospital doctor penetration, we continue to believe that there is significant room for sustained growth rate acceleration.
Sanara Medtech ($SMTI) continues to be an extremely favorable risk reward. On their fourth quarter call they offered revenue guidance of 13-17% growth in line with sell side expectations but below the 20% some hoped for. At their valuation, we believe the forecasted growth to be more than good enough and likely to be revised upward. Perhaps underappreciated is that Sanara’s products are largely distributed by third parties who, to be effective, need to be at a hospital for a procedure - to ensure Sanara’s products are used. With increasing evidence of their product’s efficacy recently released and a focus on increasing per hospital doctor penetration, we continue to believe that there is significant room for sustained growth rate acceleration.
Press Release
Articles on Sanara MedTech Inc
Headlines
See More- 1
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
